Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL363618 | 1.00 | — | — | |
| Sulfuric Acid SCHEMBL27664120 | 1.00 | CA5A (0.50) | CA5ACA5BCA2CA1TSHR | |
| Methylhydrazine SCHEMBL6952982 | 0.92 | — | — | |
| Sulfuric Acid SCHEMBL439830 | 0.82 | — | — | |
| Sulfuric Acid SCHEMBL27663032 | 0.82 | CA5A (0.60) | CA5ACA5BCA2CA1TSHR | |
| Sulfuric Acid SCHEMBL29195407 | 0.82 | CA5A (0.60) | CA5ACA5BCA2CA1TSHR | |
| Sulfuric Acid SCHEMBL166895 | 0.82 | CA5A (0.60) | CA5ACA5BCA2CA1TSHR | |
| Methylhydrazine SCHEMBL22531604 | 0.82 | — | — | |
| Methylhydrazine SCHEMBL6686580 | 0.79 | — | — | |
| Sulfamide SCHEMBL28889919 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110283094-A | A kind of synthesis technology of anticancer drug procarbazine | 苏州岚云医药科技有限公司 | 2019-09-27 | — | — | CN | claimed |
| CN-110128457-A | The preparation method of heterocycle small molecule compound | 宁波瑞奇医药科技有限公司 | 2019-08-16 | — | — | CN | claimed |
| CN-106631957-B | A kind of antitumoral compounds and the preparation method and application thereof targeting FAP-alpha enzyme | 广州药本君安医药科技股份有限公司 | 2019-05-14 | — | — | CN | claimed |
| CN-106631957-A | Antitumor compound targeting FAP-alpha enzyme and preparation method and application thereof | 广州药本君安医药科技股份有限公司 | 2017-05-10 | — | — | CN | claimed |
| CN-105175335-A | 3-(3,3-dichloroallyloxy)-1-methylpyrazole-5-formamide derivatives and preparation method thereof | UNIV NANYANG NORMAL | 2015-12-23 | — | — | CN | claimed |
| EP-1029893-B1 | Resin composition | NICHIAS CORP (JP) | 2004-12-01 | — | — | EP | claimed |
| US-20020107318-A1 | Resin Composition | NICHIAS CORPORATION (JP) | 2002-08-08 | — | — | US | claimed |
| EP-1029893-A2 | Resin composition | NICHIAS CORPORATION (JP) | 2000-08-23 | — | — | EP | claimed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| WO-2021253098-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2021-12-23 | — | — | WO | disclosed |
| CN-110506038-A | PESTICIDAL COMPOUNDS | BASF SE | 2019-11-26 | — | — | CN | disclosed |
| CN-110283094-A | A kind of synthesis technology of anticancer drug procarbazine | 苏州岚云医药科技有限公司 | 2019-09-27 | — | — | CN | disclosed |
| CN-110214136-A | Pyrazole derivatives as MALT1 inhibitor | 詹森药业有限公司 | 2019-09-06 | — | — | CN | disclosed |
| CN-110191639-A | Substituted sulfonamides for combating animal pests | 拜耳公司 | 2019-08-30 | — | — | CN | disclosed |
| US-20020107318-A1 | Resin Composition | NICHIAS CORPORATION (JP) | 2002-08-08 | — | — | US | disclosed |
| EP-1029893-A2 | Resin composition | NICHIAS CORPORATION (JP) | 2000-08-23 | — | — | EP | disclosed |
| CN-1259140-A | Treatment of insulin resistance with growth hormone secretagogues | PFIZER PROD INC (US) | 2000-07-05 | — | — | CN | disclosed |
| CN-1206422-A | Growth-hormone secretagogues | PFIZER (US) | 1999-01-27 | — | — | CN | disclosed |
| US-4957905-A | ANTIBIOTICS | BEECHAM GROUP P.L.C. (GB) | 1990-09-18 | — | — | US | disclosed |
| EP-0307176-A2 | Erythromycin derivatives | BEECHAM GROUP PLC (GB) | 1989-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227428-A1 | AMIDO COMPOUNDS | RIPK1, RIPK3, MLKL | CA5A 2487/4885CA5B 3172/4885CA2 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.